Anti-obesity agents: An update

Hao-Chang Hung, Horng-Yih Ou, Shu Hwa Hsiao, Ta Jen Wu

研究成果: Article同行評審

摘要

As the development of civilization, worldwide prevalence rates of obesity are rising and become a big social problem. Obesity-related disorders such as hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, arthritis, gallstone and even cancer had been emerging to be heavy burden for individual, family and society. Prevention and treatment of obesity are essential for the prevention of these associated disorders. The treatment of obesity will be initiated from non-pharmacological therapy. Pharmacological therapy has recently much well developed. Pharmacotherapy may have synergistic effect on the weight reduction of non-pharmacological interventions. The anti-obesity agents including sibutramine, orlistat, and rimonabant were approved by FDA. The evidence-based studies show that these agents have the effects on improving lipid profile and insulin resistance in addition to weight reduction. However, long-term studies with morbidity and mortality as clinical end-point are also expected. Many additional anti-obesity agents, some of which seem promising, are currently on developing.

原文English
頁(從 - 到)155-162
頁數8
期刊Journal of Internal Medicine of Taiwan
17
發行號4
出版狀態Published - 2006 八月 1

All Science Journal Classification (ASJC) codes

  • 內科學

指紋

深入研究「Anti-obesity agents: An update」主題。共同形成了獨特的指紋。

引用此